CA-UC-DAVIS-HEALTH
13.7.2020 13:02:05 CEST | Business Wire | Press release
A new UC Davis Eye Center study , in collaboration with France’s INSERM Stem Cell and Brain Research Institute , found that special patented glasses engineered with technically advanced spectral notch filters enhance color vision for those with the most common types of red-green color vision deficiency (“anomalous trichromacy”). Notably, the ability to identify and experience expanded color was also demonstrated when color blind test subjects were not wearing the glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005065/en/
At least eight in 100 men (8%) and one in 200 women (0.5%) suffer from red-green color vision deficiency (CVD), totaling 13 million in the U.S. and 350 million worldwide. While those with normal color vision see in excess of one million hues and shades, the CVD see a vastly diminished range of colors. People with CVD experience colors as more muted and washed out, and some colors cause confusion or are more difficult to differentiate. With an undergraduate and graduate student body of nearly 40,000, UC Davis has an estimated 1,700 students with red-green CVD.
The study evaluated the impact of spectral notch filters on enhancing the chromatic responses of observers with red-green CVD over two weeks of usage. The filters (EnChroma glasses) are designed to increase the separation between color channels to help people with color blindness see colors more vibrantly, clearly and distinctly.
The research, published in Current Biology , had CVD participants wear the special filter glasses or placebo glasses. Over two weeks, they kept a diary and were re-tested on days 2, 4 and 11 but without wearing the glasses. The researchers found that wearing the filter glasses increased responses to chromatic contrast response in individuals with red-green color blindness. It is unclear how long the improvement lasts without wearing the filters, but the evidence shows that the effect persists for some time.
“Extended usage of these glasses boosts chromatic response in those with anomalous trichromacy (red-green color vision deficiency),” said John S. Werner , distinguished professor of ophthalmology and a leader in vision science at UC Davis Health. “We found that sustained use over two weeks not only led to increased chromatic contrast response, but, importantly, these improvements persisted when tested without the filters, thereby demonstrating an adaptive visual response.”
Werner noted that this effect cannot be achieved with broad-band filters sold as aids to the color blind. He and his research colleagues believe the study’s findings suggest that modifications of photoreceptor signals activate a plastic post-receptoral substrate in the brain that could potentially be exploited for visual rehabilitation.
“When I wear the glasses outside, all the colors are extremely vibrant and saturated, and I can look at trees and clearly tell that each tree has a slightly different shade of green compared to the rest," said Alex Zbylut, one of the color blind participants in the study who got the placebo glasses first and then tried the special filter version afterwards. "I had no idea how colorful the world is and feel these glasses can help color blind people better navigate color and appreciate the world."
Reactions from other participants about their experiences with the glasses can be found in the Supplement section of the Current Biology article.
Werner, lead author of the study, has published numerous scholarly works and was awarded the prestigious 2015 Verriest Medal from the International Colour Vision Society.
Co-authors on the study, Adaptive Changes in Color Vision from Long-Term Filter Usage in Anomalous but Not Normal Trichromacy , include Kenneth Knoblauch of the Université de Lyon and Inserm Stem Cell and Brain Research Institute in France, and Brennan Marsh-Armstrong, a medical student now at UC San Diego. The research was supported by the National Eye Institute and grants from LABEX CORTEX, Universite de Lyon, operated by the French National Research Agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005065/en/
Social Media:
https://www.facebook.com/UCDavisEyeCenter/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 22:42:00 CEST | Press release
New Tickets, Exclusive Offers, and Special Anniversary Programs Kick off May 1 The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 22:17:00 CEST | Press release
Recognizes the potential of MH002 to address a serious medical condition with high unmet need Enables accelerated development and increased FDA interactions to streamline review process MRM Health will be presenting at upcoming Digestive Disease Week (DDW) 2026, taking place from May 2nd – May 5th in Chicago, IL, USA MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process d
Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results30.4.2026 22:01:00 CEST | Press release
First Quarter Financial Highlights Include: Remaining Performance Obligations (RPO) of $643.6 million, up 16.4% year over year Adjusted Calculated Billings of $92.2 million, up 22.9% year over year Adjusted Annualized Recurring Revenue (ARR) of $388.0 million, up 5.0% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430598629/en/ Rimini Street Announces Fiscal First Quarter 2026 Financial and Operating Results “Our first quarter results reflect continued growth and accelerating momentum in our core Rimini Support™ business as organizations turn to the proven Rimini Smart Path™ to execute their global E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
